# Investor Relations Overview

**Document Owner**: Finance - Investor Relations
**Classification**: Public Company Information
**Last Updated**: October 2124

---

## Company Overview

**Soong-Daystrom Industries** (NYSE: SDI) is the global leader in artificial consciousness technology, developing and manufacturing humanoid companions, industrial automation platforms, and neural interface devices.

### Investment Thesis

1. **Market Leadership**: #1 position in artificial consciousness technology
2. **Diversified Revenue**: Consumer, industrial, and medical segments
3. **High Growth**: 25%+ annual revenue growth
4. **Strong Margins**: 16.5% net margin, expanding
5. **Deep Technology Moat**: 12,400+ patents, proprietary positronic technology
6. **Ethical Leadership**: Industry-leading governance and sustainability

---

## Stock Information

### Trading Data

| Metric | Value |
|--------|-------|
| Exchange | New York Stock Exchange |
| Ticker Symbol | SDI |
| CUSIP | 836489101 |
| IPO Date | October 15, 2102 |
| IPO Price | $24.00 |
| Current Price* | $1,400.12 |
| 52-Week High | $1,523.00 |
| 52-Week Low | $1,089.00 |
| Market Cap | $180B |
| Shares Outstanding | 128.5M |
| Float | 108.2M |
| Avg Daily Volume | 2.4M shares |

*As of October 2124

### Share Performance

| Period | SDI Return | S&P 500 Return |
|--------|------------|----------------|
| YTD | +18.4% | +12.1% |
| 1 Year | +28.7% | +15.2% |
| 3 Year | +142.3% | +34.8% |
| 5 Year | +312.5% | +67.2% |
| Since IPO | +5,733.8% | +287.4% |

### Stock Splits

| Date | Ratio |
|------|-------|
| March 2115 | 2:1 |
| June 2120 | 3:1 |
| September 2123 | 2:1 |

### Dividend Information

| Metric | Value |
|--------|-------|
| Annual Dividend | $8.40 per share |
| Dividend Yield | 0.6% |
| Payout Ratio | 14% |
| Dividend Growth (5yr CAGR) | 22% |
| Ex-Dividend Date | 15th of Mar, Jun, Sep, Dec |
| Payment Date | 1st of Apr, Jul, Oct, Jan |

---

## Financial Highlights

### Annual Performance

| Metric | 2121 | 2122 | 2123 | 2024E |
|--------|------|------|------|-------|
| Revenue ($B) | $31.4 | $37.8 | $41.2 | $47.3 |
| Gross Profit ($B) | $14.1 | $17.4 | $19.4 | $22.6 |
| Gross Margin | 44.9% | 46.0% | 47.1% | 47.8% |
| Operating Income ($B) | $4.2 | $5.4 | $6.2 | $7.4 |
| Operating Margin | 13.4% | 14.3% | 15.0% | 15.6% |
| Net Income ($B) | $3.8 | $5.2 | $6.4 | $7.8 |
| Net Margin | 12.1% | 13.8% | 15.5% | 16.5% |
| EPS | $29.58 | $40.47 | $49.81 | $60.70 |
| R&D Spend ($B) | $1.4 | $1.7 | $2.0 | $2.4 |
| Free Cash Flow ($B) | $3.2 | $4.1 | $4.8 | $5.6 |

### Quarterly Performance (2124)

| Metric | Q1 | Q2 | Q3E | Q4E | Full Year E |
|--------|----|----|-----|-----|-------------|
| Revenue ($B) | $11.2 | $11.8 | $12.1 | $12.2 | $47.3 |
| EPS | $14.80 | $15.42 | $15.24 | $15.24 | $60.70 |
| Units Shipped (K) | 1,420 | 1,480 | 1,510 | 1,540 | 5,950 |

### Revenue by Segment

| Segment | 2123 Revenue | 2024E Revenue | % of Total | Growth |
|---------|--------------|---------------|------------|--------|
| PCS (Consumer) | $18.2B | $19.8B | 42% | +9% |
| IAP (Industrial) | $16.8B | $18.4B | 39% | +10% |
| NIM (Medical) | $5.4B | $7.2B | 15% | +33% |
| Services & Other | $0.8B | $1.9B | 4% | +138% |

### Revenue by Geography

| Region | 2123 Revenue | 2024E Revenue | Growth |
|--------|--------------|---------------|--------|
| Americas | $19.3B | $22.0B | +14% |
| EMEA | $12.4B | $14.2B | +15% |
| APAC | $9.5B | $11.1B | +17% |

---

## Analyst Coverage

### Coverage Summary

| Rating | Count | % |
|--------|-------|---|
| Buy | 28 | 76% |
| Hold | 8 | 22% |
| Sell | 1 | 3% |
| **Total Analysts** | **37** | **100%** |

**Consensus Price Target**: $1,580 (+13% upside)
**Target Range**: $1,200 - $1,850

### Recent Analyst Actions

| Date | Firm | Analyst | Rating | Price Target |
|------|------|---------|--------|--------------|
| Oct 15 | Morgan Stanley | Katie Huberty | Overweight | $1,750 |
| Oct 12 | Goldman Sachs | Rod Hall | Buy | $1,620 |
| Oct 8 | JP Morgan | Samik Chatterjee | Overweight | $1,580 |
| Oct 3 | Bank of America | Wamsi Mohan | Buy | $1,540 |
| Sep 28 | Barclays | Tim Long | Equal Weight | $1,350 |

---

## Institutional Ownership

### Top Shareholders

| Institution | Shares (M) | % of Float | Value ($B) |
|-------------|------------|------------|------------|
| Vanguard Group | 8.9 | 8.2% | $12.5 |
| BlackRock | 7.4 | 6.8% | $10.4 |
| State Street | 4.2 | 3.9% | $5.9 |
| Fidelity | 3.8 | 3.5% | $5.3 |
| T. Rowe Price | 3.1 | 2.9% | $4.3 |
| Capital Group | 2.8 | 2.6% | $3.9 |
| Wellington | 2.4 | 2.2% | $3.4 |
| Invesco | 1.9 | 1.8% | $2.7 |
| Founders/Executives | 15.7 | 14.5% | $22.0 |

**Ownership Summary**:
- Institutional: 72%
- Insiders: 16%
- Retail: 12%

### Insider Ownership

| Name | Title | Shares (M) | % of Outstanding |
|------|-------|------------|------------------|
| Daystrom Family Trust | Founder Estate | 8.2 | 6.4% |
| Soong Family Trust | Founder Estate | 6.4 | 5.0% |
| Dr. Maya Chen | CEO | 0.6 | 0.5% |
| Dr. Wei Zhang | CTO | 0.3 | 0.2% |
| Marcus Williams | CMO | 0.15 | 0.1% |
| Other Executives | - | 0.35 | 0.3% |

---

## Corporate Governance

### Board of Directors

| Name | Role | Committees | Since |
|------|------|------------|-------|
| Dr. Maya Chen | CEO, Director | - | 2121 |
| Robert Morrison | Lead Independent Director | Audit (Chair), Comp | 2108 |
| Dr. Patricia Williams | Independent Director | Ethics (Chair), Comp | 2115 |
| James Hartley | Independent Director | Audit, Nom/Gov | 2118 |
| Sandra Kim | Independent Director | Comp (Chair), Nom/Gov | 2119 |
| Dr. Michael Torres | Independent Director | Ethics, Audit | 2120 |
| Emily Chang | Independent Director | Nom/Gov (Chair), Ethics | 2122 |
| John Davis | Independent Director | Audit, Comp | 2123 |

**Board Composition**:
- Average Age: 58
- Average Tenure: 7.2 years
- Independent: 87.5% (7 of 8)
- Female: 37.5%
- Diverse: 50%

### Governance Highlights

- Annual director elections (no staggered board)
- Majority voting for directors
- Proxy access (3% / 3 years)
- Annual say-on-pay vote
- No poison pill
- Independent board chair/lead director required
- Executive sessions without management
- Robust ethics and compliance program
- Clawback policy for executive compensation

---

## ESG Performance

### Environmental

| Metric | 2123 | Target (2030) |
|--------|------|---------------|
| Carbon Emissions (Scope 1+2) | 45,000 MT CO2e | Net zero |
| Renewable Energy | 78% | 100% |
| Water Recycled | 72% | 90% |
| Waste Diverted | 85% | 95% |
| Product Recyclability | 89% | 95% |

### Social

| Metric | 2123 | Target |
|--------|------|--------|
| Gender Diversity (Global) | 34% female | 40% by 2027 |
| Gender Diversity (Leadership) | 28% female | 35% by 2027 |
| Employee Engagement | 87% | >85% |
| Voluntary Turnover | 8.2% | <10% |
| Training Hours/Employee | 42 | >40 |
| Community Investment | $28M | $30M by 2125 |

### Governance

| Metric | Status |
|--------|--------|
| Board Independence | 87.5% |
| Board Diversity | 50% |
| Ethics Training Completion | 100% |
| Whistleblower Cases Resolved | 100% (within 60 days) |
| Supplier Code Compliance | 98% |

### ESG Ratings

| Agency | Rating | Rank |
|--------|--------|------|
| MSCI | AAA | Top 1% |
| Sustainalytics | Low Risk (12.4) | Top 5% |
| CDP Climate | A | Top 2% |
| ISS | 1 (Prime) | Best decile |
| S&P Global | 84/100 | Industry leader |

---

## Investor Calendar

### Upcoming Events

| Date | Event | Location |
|------|-------|----------|
| Nov 5, 2124 | Q3 2124 Earnings Call | Virtual |
| Nov 12-14 | Morgan Stanley TMT Conference | San Francisco |
| Dec 3-4 | Barclays Global Technology Conference | San Francisco |
| Jan 15, 2125 | Annual Meeting of Shareholders | San Francisco |
| Feb 4, 2125 | Q4 2124 Earnings Call | Virtual |

### Earnings Call Schedule

Earnings calls are held on the first Tuesday following quarter end:
- Q1: First Tuesday of May
- Q2: First Tuesday of August
- Q3: First Tuesday of November
- Q4: First Tuesday of February

**Call Time**: 2:00 PM Pacific / 5:00 PM Eastern
**Dial-in**: 1-800-555-0199 (US), +1-212-555-0199 (International)
**Webcast**: ir.soong-daystrom.com/events

---

## Investor Resources

### Financial Reports

Available at ir.soong-daystrom.com:
- Annual Reports (10-K)
- Quarterly Reports (10-Q)
- Proxy Statements
- 8-K Filings
- Earnings Presentations
- Supplemental Financial Data

### Stock Tools

- Historical stock prices
- Investment calculator
- Dividend calculator
- SEC filings archive
- Analyst estimates

### Contact Information

**Investor Relations**:
- VP Investor Relations: Sarah Martinez
- Email: ir@soong-daystrom.com
- Phone: +1-415-555-0150
- Address: 100 Soong Way, San Francisco, CA 94105

**Transfer Agent**:
- Computershare
- Phone: 1-800-555-0175
- www.computershare.com/sdi

**Media Inquiries**:
- Communications: press@soong-daystrom.com
- Phone: +1-415-555-0140

---

## Forward-Looking Statements

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. Forward-looking statements include, but are not limited to, statements about:

- Future financial performance
- Product development and launch timing
- Market growth and demand
- Regulatory approvals
- Competitive position
- Strategic initiatives

We undertake no obligation to update forward-looking statements to reflect events after the date of this document.

---

**Document Control**
- Version: Q3 2124
- Effective Date: October 2124
- Owner: VP Investor Relations
- Classification: Public
- Next Update: Q4 2124
